批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/07/10 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/07/10 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/07/10 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/07/10 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/07/10 |
SUPPL-7(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/07/10 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/04/15 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2014/10/27 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
2011/11/07 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:LEVOCETIRIZINE DIHYDROCHLORIDE 剂型/给药途径:SOLUTION;ORAL 规格:2.5MG/5ML 治疗等效代码:AA
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
091263 |
001 |
ANDA |
LEVOCETIRIZINE DIHYDROCHLORIDE |
LEVOCETIRIZINE DIHYDROCHLORIDE |
SOLUTION;ORAL |
2.5MG/5ML |
Prescription |
No |
Yes |
AA |
2011/11/07
|
PADAGIS US |
202673 |
001 |
ANDA |
LEVOCETIRIZINE DIHYDROCHLORIDE |
LEVOCETIRIZINE DIHYDROCHLORIDE |
SOLUTION;ORAL |
2.5MG/5ML |
Prescription |
No |
No |
AA |
2013/07/26
|
TARO |
204599 |
001 |
ANDA |
LEVOCETIRIZINE DIHYDROCHLORIDE |
LEVOCETIRIZINE DIHYDROCHLORIDE |
SOLUTION;ORAL |
2.5MG/5ML |
Prescription |
No |
No |
AA |
2017/05/15
|
CHARTWELL MOLECULAR |
210914 |
001 |
ANDA |
LEVOCETIRIZINE HYDROCHLORIDE |
LEVOCETIRIZINE DIHYDROCHLORIDE |
SOLUTION;ORAL |
2.5MG/5ML |
Prescription |
No |
No |
AA |
2019/04/01
|
HETERO LABS LTD III |